Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-713-3699
Debt
Current Ratio0.78
Quick Ratio0.75
Price-To-Earnings
Sales & Book Value
Annual Sales$28.48 million
Price / Sales18.26
Price / Cash FlowN/A
Price / Book4.89
Profitability
Net Income$-74,860,000.00
Net Margins-30.13%
Return on Assets-11.34%
Miscellaneous
Employees250
OptionableOptionable
Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions
What is Collegium Pharmaceutical's stock symbol?
Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."
How were Collegium Pharmaceutical's earnings last quarter?
Collegium Pharmaceutical Inc (NASDAQ:COLL) issued its quarterly earnings data on Thursday, November, 8th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.14. The specialty pharmaceutical company earned $70.20 million during the quarter, compared to analyst estimates of $74.79 million. Collegium Pharmaceutical had a negative net margin of 30.13% and a negative return on equity of 70.06%. The firm's revenue was up 485.0% compared to the same quarter last year. During the same period last year, the business earned ($0.45) EPS. View Collegium Pharmaceutical's Earnings History.
When is Collegium Pharmaceutical's next earnings date?
What price target have analysts set for COLL?
7 Wall Street analysts have issued 1-year price targets for Collegium Pharmaceutical's stock. Their predictions range from $27.00 to $35.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $32.6667 in the next year. This suggests a possible upside of 108.9% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.
What is the consensus analysts' recommendation for Collegium Pharmaceutical?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.
What are Wall Street analysts saying about Collegium Pharmaceutical stock?
Here are some recent quotes from research analysts about Collegium Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. " (1/10/2019)
- 2. Cantor Fitzgerald analysts commented, ". We are reiterating our Overweight rating and 12-month price target of $35 post COLL issuing 2019 revenue guidance below FactSet consensus, and our estimates. We remain positive on the long-term growth potential of Xtampza, and we believe that Xtampza will replace OxyContin as the largest branded oxycodone ER product over time with COLL building itself into one of the leading specialist pain companies." (1/7/2019)
Has Collegium Pharmaceutical been receiving favorable news coverage?
Media stories about COLL stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Collegium Pharmaceutical's key competitors?
Some companies that are related to Collegium Pharmaceutical include Arena Pharmaceuticals (ARNA), Xencor (XNCR), Heron Therapeutics (HRTX), Allakos (ALLK), Mirati Therapeutics (MRTX), Supernus Pharmaceuticals (SUPN), Endocyte (ECYT), Innoviva (INVA), Ironwood Pharmaceuticals (IRWD), AnaptysBio (ANAB), Myokardia (MYOK), Zogenix (ZGNX), PTC Therapeutics (PTCT), Madrigal Pharmaceuticals (MDGL) and Insmed (INSM).
Who are Collegium Pharmaceutical's key executives?
Collegium Pharmaceutical's management team includes the folowing people:
- Mr. Michael T. Heffernan, Co-Founder & Chairman (Age 55)
- Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 48)
- Mr. Paul J. Brannelly, Exec. VP & CFO (Age 46)
- Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 44)
- Ms. Alex Dasalla, Head of Investor Relations
When did Collegium Pharmaceutical IPO?
(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.
How do I buy shares of Collegium Pharmaceutical?
Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Collegium Pharmaceutical's stock price today?
One share of COLL stock can currently be purchased for approximately $15.64.
How big of a company is Collegium Pharmaceutical?
Collegium Pharmaceutical has a market capitalization of $530.30 million and generates $28.48 million in revenue each year. The specialty pharmaceutical company earns $-74,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Collegium Pharmaceutical employs 250 workers across the globe.
What is Collegium Pharmaceutical's official website?
How can I contact Collegium Pharmaceutical?
Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.
MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
